How should cervical intra‑epithelial neoplasia grade 1 (CIN 1) be managed during pregnancy?

Management of CIN 1 in Pregnancy

CIN 1 diagnosed during pregnancy should be managed with observation only—treatment is deferred until the postpartum period, as the risk of progression to invasive cancer during pregnancy is minimal and spontaneous regression rates are high. 1

Core Management Principles

No Treatment During Pregnancy

• The only indication for treatment of cervical neoplasia in pregnant women is invasive cancer. 1
• Treatment procedures (excision or ablation) during pregnancy are associated with complications and high rates of recurrence or persistence. 1
• CIN 1 has an extremely low progression rate to invasive cancer (0.3% in general populations), making aggressive intervention during pregnancy unnecessary. 2

Surveillance Strategy During Pregnancy

Initial Evaluation:

• Colposcopy should be performed to confirm the diagnosis and rule out higher-grade lesions or invasive disease. 3, 4
• Colposcopic-directed biopsy is safe during pregnancy, though subjectively associated with increased bleeding without increased complications. 4
• Endocervical curettage (ECC) must NOT be performed during pregnancy to avoid potential disruption of the pregnancy. 3, 4

Follow-up Protocol:

• Repeat cytology and colposcopy can be deferred until 6 weeks postpartum for low-grade lesions like CIN 1. 3
• If colposcopy is performed during pregnancy and shows no suspicion of high-grade disease or invasion, further surveillance during pregnancy may be limited. 4
• Biopsy should only be repeated during pregnancy if there is colposcopic suspicion of progression to high-grade disease or invasion. 4

Natural History in Pregnancy

High Spontaneous Regression Rates:

• CIN 1 shows significantly higher spontaneous regression rates during pregnancy compared to non-pregnant women (69% vs 48.7%). 5
• Another study demonstrated 56.9% regression in pregnant women versus 31.4% in non-pregnant controls. 6
• Complete remission rates reach 41.2% postpartum. 6

Low Progression Risk:

• Progression to CIN 2-3 during pregnancy occurs in only 14.3% of cases. 5
• No progression to invasive cancer has been observed in properly followed pregnant women with CIN 1. 6, 5
• The persistence rate is significantly lower in pregnancy (39.2%) compared to non-pregnant women (58.8%). 6

Postpartum Management

Timing of Reevaluation:

• Schedule cytology and colposcopy 3-6 months postpartum (typically 6 weeks to 6 months). 5, 7
• This allows time for pregnancy-related cervical changes to resolve. 7

Postpartum Management Options:

• If CIN 1 persists postpartum, follow standard non-pregnant guidelines: observation with repeat cytology every 6-12 months or HPV testing at 12 months. 1
• If repeat cytology shows ASC-US or greater, or HPV testing is positive, repeat colposcopy is indicated. 1
• After 2 years of persistent CIN 1, either continued follow-up or treatment (ablation or excision) is acceptable based on patient and provider preferences. 1

Important Caveats

Mode of Delivery:

• Mode of delivery does not definitively affect persistence of CIN postpartum. 4
• Vaginal delivery may contribute to regression through loss of dysplastic epithelium during cervical ripening. 7

When to Suspect Higher-Grade Disease:

• If CIN 1 was preceded by HSIL or atypical glandular cells (AGC) cytology, there is higher risk of missed CIN 2-3 (23-55% in some series). 2, 1
• In these cases, more vigilant surveillance or consideration of postpartum excisional procedure may be warranted. 1

Contraindications to Observation:

• Suspicion of invasive cancer on colposcopy requires excisional biopsy even during pregnancy, but only when results would alter oncologic or pregnancy management. 4
• This is the only scenario where excisional procedures are acceptable during pregnancy for CIN lesions. 4